MX2019006207A - Forma polimorfica de sepiapterina. - Google Patents

Forma polimorfica de sepiapterina.

Info

Publication number
MX2019006207A
MX2019006207A MX2019006207A MX2019006207A MX2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A
Authority
MX
Mexico
Prior art keywords
crystalline form
sepiapterin
polymorphic form
dysfunction
patient
Prior art date
Application number
MX2019006207A
Other languages
English (en)
Inventor
E Levy Daniel
Yoshino Hiroshi
Komoda Taichi
Matsumoto Takayoshi
Kishimoto Kaito
MURATA Shunichi
Shiro Yuichi
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MX2019006207A publication Critical patent/MX2019006207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una forma cristalina de sepiapterina, un método para preparar la forma cristalina, composiciones farmacéuticas que contienen la forma cristalina y un método para someter a tratamiento a pacientes con una enfermedad asociada con bajos niveles intracelulares de BH4 o con una disfunción de diversas vías metabólicas dependientes del BH4, que implica administrarle al paciente una cantidad eficaz de la forma cristalina.
MX2019006207A 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina. MX2019006207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
PCT/US2017/063515 WO2018102314A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Publications (1)

Publication Number Publication Date
MX2019006207A true MX2019006207A (es) 2019-11-18

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006207A MX2019006207A (es) 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina.

Country Status (8)

Country Link
US (2) US11130760B2 (es)
EP (1) EP3548487A4 (es)
JP (1) JP7148532B2 (es)
CN (1) CN110312721A (es)
CA (1) CA3043499A1 (es)
MA (1) MA46972A (es)
MX (1) MX2019006207A (es)
WO (1) WO2018102314A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
US11617752B2 (en) 2018-05-30 2023-04-04 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
KR20210038848A (ko) * 2018-05-30 2021-04-08 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 제약상 허용되는 염
WO2021026247A1 (en) 2019-08-05 2021-02-11 Ptc Therapeutics Mp, Inc. Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
EP4093405A1 (en) 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
EP4291190A1 (en) 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating glioblastomas with sepiapterin
US20240122931A1 (en) 2021-02-09 2024-04-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
CA3232498A1 (en) * 2021-09-29 2023-04-06 Akm Nasir Uddin Pharmaceutical composition of sepiapterin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
AU2004311544A1 (en) 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
BRPI0416566A (pt) 2003-11-17 2007-01-23 Biomarin Pharm Inc tratamento de fenilcetonúrias com bh4
WO2005049614A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
MX2007005039A (es) 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
KR101277074B1 (ko) 2005-04-28 2013-06-25 다이이찌 산쿄 가부시키가이샤 히드라존 유도체의 제조방법
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
DK2139485T3 (da) 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
IN2014DN09053A (es) * 2012-05-07 2015-05-22 Shiratori Pharm
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用

Also Published As

Publication number Publication date
WO2018102314A1 (en) 2018-06-07
MA46972A (fr) 2019-10-09
US20200010469A1 (en) 2020-01-09
CN110312721A (zh) 2019-10-08
EP3548487A4 (en) 2020-04-29
CA3043499A1 (en) 2018-06-07
US11130760B2 (en) 2021-09-28
US20220081443A1 (en) 2022-03-17
JP2020500931A (ja) 2020-01-16
EP3548487A1 (en) 2019-10-09
JP7148532B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2019006207A (es) Forma polimorfica de sepiapterina.
EA201790693A1 (ru) Коррекция фигуры
PH12017502425A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
PH12016502353A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
PH12016502352A1 (en) Pharmaceutical composition
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PH12017501134A1 (en) Fumagillol derivatives
MX2019014940A (es) Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6).
UA89069U (uk) Спосіб корекції активності ферментів крові індиків за протозойних інвазій
MX2017007990A (es) Métodos para reducir la agregación plaquetaria y tratar enfermedades cardiovasculares y otros transtornos médicos.
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця
IN2014DE00822A (es)
RU2016116881A (ru) Препарат-стимулятор для предпосевной обработки семян